| P/E (FY) | — | Sales (TTM) | $418.2M |
| Earnings (TTM) | -$7.4M | ROE | — |
| Net Margin | −5.63% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 74.80% |
Esperion Therapeutics is a biopharmaceutical company that develops and commercializes medicines for patients with elevated LDL cholesterol in the United States. Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), oral once-daily non-statin treatments for primary hyperlipidemia, along with NILEMDO and NUSTENDI. The company has license and collaboration agreements with Daiichi Sankyo and Otsuka Pharmaceutical.
| Market Cap | $818.6M | Trading Days | 3280 |
| 52W High | 4.17 |
| 52W Low | 1.10 |
| % Off High | −23.83% |
| YTD | −14.05% | 1Y | 181.42% |
| 3Y | 113.42% | 5Y | −82.01% |
| 10Y | −71.48% | Since incept. (ann.) | −10.98% |
| Ann. Volatility (1Y) | 90.55% | Ann. Volatility (3Y) | 89.07% |
| Sharpe (1Y) | 1.51 | Sharpe (3Y) | 0.73 |
| Max Drawdown (1Y) | −53.19% | Max Drawdown (3Y) | −80.94% |
| Beta (3Y, vs SPY) | 3.79 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| OMER | OMEROS CORP | $816.4M | — |
| CMMB | Chemomab Therapeutics Ltd. | $822.8M | 79.4 |
| KURA | Kura Oncology, Inc. | $826.5M | — |
| ANNX | Annexon, Inc. | $770.9M | — |
| TBPH | Theravance Biopharma, Inc. | $870.7M | 8.2 |
| ABUS | Arbutus Biopharma Corp | $871.1M | — |
| CYRX | Cryoport, Inc. | $764.6M | 10.8 |
| AMPH | Amphastar Pharmaceuticals, Inc. | $888.5M | 9.9 |
| ACRS | Aclaris Therapeutics, Inc. | $744.4M | — |
| DSGN | Design Therapeutics, Inc. | $741.4M | — |
| JANX | Janux Therapeutics, Inc. | $914.8M | — |
| Monopar Therapeutics |
| $730.8M |
| — |
